Blinatumomab Induced Response of Multiply Refractory Multiple Myeloma in the Context of Secondary Pre-B Cell Acute Lymphoblastic Leukemia

Pratz, Keith W.

doi:10.26420/annhematoloncol.2017.1174

Cited by 6 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient, a 70-year-old female, developed pre-B-ALL while undergoing lenalidomide therapy for MM, for which she was in partial remission. She underwent cytoreductive therapy and began blinatumomab induction, which resulted in a complete remission of her ALL and a very good partial response of her MM by International Myeloma Working Group criteria (172). Although this case is promising for the application of blinatumomab to other MM patients, it is important to point out that this patient's MM cells stained positive for CD19, which is atypical for MM tumors (172).…”

Section: Clinical Trials Of Cd19-targeting Bsabs Blinatumomabmentioning

confidence: 84%

“…It has been proposed that CD19 loss aids MM cell proliferation (170), and this loss precludes MM patients from benefitting from anti-CD19 therapies. However, there have been reports of R/R MM patients responding to anti-CD19 CAR T cell therapies in combination with other treatments (171,172). Additionally, super-resolution microscopy has shown very low CD19 expression on MM cells, which was undetectable by flow cytometry but may be accessible to antibodies and modified effector cells (173).…”

Section: Cd19mentioning

confidence: 99%

“…The study consists of administering up to two 28-day cycles of blinatumomab to patients who previously received high-dose melphalan and autoSCT for MM, with results pending. A case study of blinatumomab-induced response of R/R MM in the context of a secondary pre-B cell ALL emerged in 2017 (172). The patient, a 70-year-old female, developed pre-B-ALL while undergoing lenalidomide therapy for MM, for which she was in partial remission.…”

Section: Clinical Trials Of Cd19-targeting Bsabs Blinatumomabmentioning

confidence: 99%

See 2 more Smart Citations

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

et al. 2020

View full text Add to dashboard Cite

Multiple myeloma (MM) is a plasma cell malignancy and the second most common hematological neoplasm in adults, comprising 1.8% of all cancers. With an annual incidence of ∼30,770 cases in the United States, MM has a high mortality rate, leading to 12,770 deaths per year. MM is a genetically complex, highly heterogeneous malignancy, with significant inter-and intra-patient clonal variability. Recent years have witnessed dramatic improvements in the diagnostics, classification, and treatment of MM. However, patients with high-risk disease have not yet benefited from therapeutic advances. Highrisk patients are often primary refractory to treatment or relapse early, ultimately resulting in progression toward aggressive end-stage MM, with associated extramedullary disease or plasma cell leukemia. Therefore, novel treatment modalities are needed to improve the outcomes of these patients. Bispecific antibodies (BsAbs) are immunotherapeutics that simultaneously target and thereby redirect effector immune cells to tumor cells. BsAbs have shown high efficacy in B cell malignancies, including refractory/relapsed acute lymphoblastic leukemia. Various BsAbs targeting MM-specific antigens such as B cell maturation antigen (BCMA), CD38, and CD138 are currently in pre-clinical and clinical development, with promising results. In this review, we outline these advances, focusing on BsAb drugs, their targets, and their potential to improve survival, especially for high-risk MM patients. In combination with current treatment strategies, BsAbs may pave the way toward a cure for MM.

show abstract

Section: Clinical Trials Of Cd19-targeting Bsabs Blinatumomabmentioning

confidence: 84%

Section: Cd19mentioning

confidence: 99%

Section: Clinical Trials Of Cd19-targeting Bsabs Blinatumomabmentioning

confidence: 99%

See 1 more Smart Citation

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Currently, no further studies are evaluating AMG 420 based on the pharmacokinetics mentioned earlier. However, a study evaluating AMG 701, an extended half-life BiTE without the need for continuous infusion, is in progress [22].…”

Section: Types Of Bispecific Antibodiesmentioning

confidence: 99%

Role of Bispecific antibody for Multiple Myeloma; A literature Review

Waleed¹

2021

J Oncol Res Rev Rep

View full text Add to dashboard Cite

Multiple myeloma (MM), as defined by a clonal plasma cell proliferation, manifests as end organ damage caused by the abnormally high monoclonal paraprotein.In this article, we have reviewed the potential benefits of Bispecific antibodies (BsAbs) in MM patients. In addition, new BsAbs developments and clinical trials for various MM targets are discussed in detail. Bispecific antibodies are the types of antibodies that have two different antigen binding sites in one molecule. There are 100 different classes of BsAb and all these can be divided into 2 main categories based on their fragments and both categories are under trials for MM.Despite some studies showing adverse effects development of these new treatments is going to greatly contribute to improve outcomes for a wide group of patients which also requires further clinical studies to be conducted with focus on demonstration of efficacy and safety profile.

show abstract

“…Pratz et al reported on a patient with RRMM and secondary ALL who received two cycles of blinatumomab at a dose of 28 µg/d. This patient achieved a MRD negative CR of ALL and a very good partial remission (VGPR) of MM [ 58 ]. Moreover, a systematic investigation of blinatumomab for the treatment of RRMM patients was intended within a pilot study (NCT03173430).…”

Section: Clinical Development Of Bsabs For MMmentioning

confidence: 99%

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma

Zhou

Einsele

Danhof

2020

JCM

View full text Add to dashboard Cite

Despite the introduction of novel agents such as proteasome inhibitors, immunomodulatory drugs, and autologous stem cell transplant, multiple myeloma (MM) largely remains an incurable disease. In recent years, monoclonal antibody-based treatment strategies have been developed to target specific surface antigens on MM cells. Treatment with bispecific antibodies (bsAbs) is an immunotherapeutic strategy that leads to an enhanced interaction between MM cells and immune effector cells, e.g., T-cells and natural killer cells. With the immune synapse built by bsAbs, the elimination of MM cells can be facilitated. To date, bsAbs have demonstrated encouraging results in preclinical studies, and clinical trials evaluating bsAbs in patients with MM are ongoing. Early clinical data show the promising efficacy of bsAbs in relapsed/refractory MM. Together with chimeric antigen receptor-modified (CAR)-T-cells, bsAbs represent a new dimension of precision medicine. In this review, we provide an overview of rationale, current clinical development, resistance mechanisms, and future directions of bsAbs in MM.

show abstract

Blinatumomab Induced Response of Multiply Refractory Multiple Myeloma in the Context of Secondary Pre-B Cell Acute Lymphoblastic Leukemia

Cited by 6 publications

References 4 publications

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

Role of Bispecific antibody for Multiple Myeloma; A literature Review

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma

Contact Info

Product

Resources

About